Nav: Home

Responses to treatment, outcomes of autoimmune cerebellar ataxia

September 28, 2015

While autoimmune cerebellar ataxia (a loss of muscle coordination) can lead to severe disability with some patients becoming wheelchair-bound, there are factors that may help to predict better immunotherapy response and neurological outcomes, according to an article published online by JAMA Neurology.

Autoimmune cerebellar ataxia in adults, which usually comes on rapidly and progresses quickly, can be divided into disorders that are paraneoplastic (triggered by cancer in the body) or nonparaneoplastic (non-cancer-related autoimmune disorders of the central nervous system). The disabling neurological effects can include speech that is not clearly articulated, gait and balance disorders, and loss of muscle control in the limbs. Little has been published regarding treatment responses and neurologic outcomes among patients with autoimmune cerebellar ataxia. However, at least 17 autoantibodies have been reported as causally linked to autoimmune cerebellar ataxia.

Andrew McKeon, M.D., of the Mayo Clinic, Rochester, Minn., and coauthors reviewed medical records at the Mayo Clinic to examine treatment responses and outcomes in 118 adults with autoimmune cerebellar ataxia who were seropositive for at least one neural autoantibody, had received at least one immunotherapy or cancer therapy, and had neurologist-reported outcomes from 1989 through 2013.

Results indicate the median (midpoint) age at onset of neurologic symptoms was 58, nearly three-quarters of the patients were women, and the median duration from symptom onset to last follow-up was 25 months. Among the patients, 63 had paraneoplastic ataxic disorders and 55 patients had nonparaneoplastic ataxic disorders. Also, 81 patients were seropositive for NNC [neuronal nuclear and/or cytoplasmic] antibodies; 22 patients for neural PMP [plasma membrane protein] receptor or ion channel antibodies; and 15 patients for antibodies from both categories.

Overall, 54 patients (45.8 percent) had physician-reported neurologic improvement with immunotherapy (n=51) or cancer therapy (n=3), according to the study results. Analyses suggest factors that may predict better immunotherapy response and neurologic outcomes include a nonparaneoplastic disorder, the detection of at least one or more PMP antibodies or the detection of GAD 65 [glutamic acid decarboxylase 65-kDa isoform] antibodies.

Regardless of the response to immunotherapy, the final ambulatory outcomes regarding the use of gait aids to get around were 56 patients used a wheelchair, 26 patients had walkers and seven patients used canes. Among the remaining 29 patients, 25 of them required no gait aid but had an abnormal gait and four patients had normal gait, the study reports.

"Although autoimmune ataxia is usually severe, treatment responses can be gratifying, particularly in patients with nonparaneoplastic disorders and in those harboring autoantibodies directed against GAD65 or neural PMPs," the study concludes.
(JAMA Neurol. Published online September 28, 2015. doi:10.1001/jamaneurol.2015.2378. Available pre-embargo to the media at

Editor's Note: An author made a conflict of interest disclosure. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Media Advisory: To contact corresponding author Andrew McKeon, M.D., call Dusanka Anastasijevic at 507-284-5005 or email

To place an electronic embedded link in your story: Links will be live at the embargo time:

The JAMA Network Journals

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...